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Background: Plasmodium falciparum apical membrane antigen-1 (PfAMA-1) and the 19-kDa C-terminal region
of merozoite surface protein-1 (PfMSP-119) are candidate malaria vaccine antigens expressed on merozoites and
sporozoites. This investigation was performed to evaluate simultaneously the naturally-acquired antibodies to
PfAMA-1 and PfMSP-119 and to compare IgG subclass profiles to both antigens in naturally exposed individuals
living in malaria hypoendemic areas in Iran to determine which antigen has better ability to detect sero-positive
individuals infected with P. falciparum.
Methods: In this investigation, 101 individuals from the malaria-endemic areas in Iran were examined. PfAMA-1 and
PfMSP-119 were expressed in Escherichia coli, and IgG isotype composition of naturally acquired antibodies to the
antigens (as single or in combination) was measured by ELISA assay.
Results: The result showed that 87.1% and 84.2% of the studied individuals had positive anti-PfAMA-1 and -PfMSP-119
IgG antibody responses, respectively, and the prevalence of responders did not differ significantly (P > 0.05). Moreover,
IgG1 and IgG3 were predominant over IgG2 and IgG4 antibodies and the prevalence of IgG and its subclasses to two
tested antigens had no significant correlation with age and exposure (P > 0.05). The present data confirmed that when
recombinant PfAMA-1 and recombinant PfMSP-119 antigens were combined in ELISA at equal ratios of 200 ng (100 ng
each antigen/well) and 400 ng (200 ng each antigen/well), 86.1% and 87.1% of positives sera were detected among
the examined samples, respectively.
Conclusions: The two tested recombinant antigens are immunogenic molecules, and individuals in low transmission
areas in Iran could develop and maintain equal immune responses to PfAMA-1 and PfMSP-119. Therefore, these results
could support the design of a universal PfAMA-1- and PfMSP-119-based vaccine. Also, both recombinant antigens could
be used in combination as reliable serology markers to perform immuno-epidemiological studies in malaria-endemic
areas of Iran during elimination strategy. The present information could be of use in control and elimination programmes
in Iran and other similar malaria settings.
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Malaria is caused by different obligate intracellular para-
sites. Plasmodium falciparum is one the most lethal species
of malaria parasites that infects humans [1]. This parasite
species is responsible for most of the pathology associated
with the disease [2]. The unacceptable health burden of
malaria and its economical and social impacts have led to
making a plan for scaling-up malaria control, elimination,
and global eradication [3]. However, the hopes of achieving
this goal are diminishing due to the limited effective control
tools, the emergence and rapid widespread occurrence of
drug-resistant parasites, and the resistance of mosquitoes
to insecticides.
Therefore, a search for new tools is required to control
or eliminate malaria. One of the effective tools to combat
infectious diseases is vaccination [4]. Hence, to design an
efficient malaria vaccine, it is essential to determine the
key target antigen that induces protective immunity for
applying in vaccine development [5].
Immuno-epidemiological studies in diverse malaria-
endemic regions with different level of transmission and
human genetic background provide more information to
understand the host immune response to P. falciparum,
and also it may help to design an effective vaccine
against this species. For instance, individuals who are
living in endemic areas are simultaneously and repeat-
edly challenged with numerous malaria antigens. In high
transmission regions, all individuals have many infections
during their life; therefore, protective immunity develops
with age/exposure in these individuals [6]. In contrast, in
low and unstable transmission regions, there is a lack of
such correlation with age [7-12].
A passive transfer study conducted in the 1960s showed
that IgG antibody is a major component of naturally-
acquired protective immune responses of P. falciparum
[13,14]. In malaria-endemic areas, older children and
adults develop naturally-acquired immunity to malaria
but remain susceptible to infection.
In the life cycle of human malaria parasites, the invasion
of erythrocytes by merozoites (the only extracellular stage
of the asexual cycle) is an obligatory step during blood-
stage infection, and blocking this step with antibodies
would lead to hinder the invasion of red blood cells
[13,15,16]. The proteins that are present on the surface of
invasive merozoites of Plasmodium are essential targets
for development of an effective malaria vaccine. Among
them, merozoite surface protein-1 (MSP-1) and apical
membrane antigen-1 (AMA-1) are considered leading and
attractive malaria blood-stage vaccine candidate antigens
[17-21]. These two antigens are located on the merozoite
surface and undergo proteolytic processing before the
invasion of merozoite into the red blood cells.
AMA-1 is a type I integral membrane protein expressed
on merozoites and sporozoites and initially located in themicronemes [22-25]. AMA-1 is synthesized in segmenting
schizonts as an 83-kDa precursor protein. At about the
time of merozoite release and erythrocyte invasion, the
prodomain is cleaved to a 66 kDa membrane-bound form
[26,27], where it is subsequently shed as 44- and 48-kDa
forms [27,28]. This protein has three subdomains defined
by their disulfide bonds [29] and contains 16 conserved
cysteine residues forming eight intra molecular disulfide
bonds [26]. Furthermore, individuals living in areas where
malaria is endemic have antibodies against AMA-1
[30-32], and these antibodies efficiently inhibit the process
of red blood cells invasion in vitro [28,31,33]. The protect-
ive efficacy of AMA-1-based vaccines against parasite
challenge has been demonstrated in many rodent and
monkey models [22,34,35].
MSP-1 is synthesized as a 195-kDa protein and sequen-
tially processed into a cysteine-rich 19-kDa fragment
(MSP-119) [36]. This protein contains two epidermal
growth factor (EGF)-like domains [37,38]. Several in vitro
and in vivo studies have shown that the PfMSP-119 is an
ideal target for blocking parasite invasion into the erythro-
cyte [39-43]. Antibodies to PfMSP-119 are found in the
majority of malaria-exposed individuals from endemic
areas [44,45], and these antibodies correlate with the
development of clinical immunity against P. falciparum
malaria [44,46].
In Iran, malaria is hypoendemic with seasonal trans-
mission. In 2013, due to elimination strategies, about
1,373 malaria cases were reported from Iran that more
than 80% of these cases were Plasmodium vivax and the
rest of them were P. falciparum (the Ministry of Health,
2013, unpublished). In this area, there is no record of
severe malaria or death due to malaria. Most of the
patients are adults and may experience several infections
by P. falciparum and P. vivax with clinical symptoms. As
a continuation of the previous immuno-epidemiological
studies in Iran [10,11,47-49], in the present study, the
main objective was to evaluate simultaneously the natur-
ally acquired antibodies responses to two recombinant
proteins of P. falciparum (PfMSP-119 and PfAMA-1)
among falciparum malaria subjects in the hypoendemic
areas of Iran.
These two antigens were selected for this study because
the evidence showed that there is likely a association
between the presence of antibodies to these antigens
and protection [50,51]. In fact, it demonstrates that
both antigens are potential asexual erythrocytic stage
vaccine candidates. Therefore, the main objective of the
present work was to evaluate and compare the profile
of IgG subclass-specific responses to PfAMA-1 and
PfMSP-119 in naturally exposed individuals living in the
malaria hypoendemic areas, Iran. Also, the association
between naturally acquired anti-PfAMA-1 and -PfMSP-
119 isotype responses and host age and exposure was
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are used as a mean of detection of antibody responses in
areas of low endemicity [52-55]; therefore, the second
objective of the present study was to determine which anti-
gen has better ability to detect sero-positive individuals
infected with P. falciparum. The current information could
be of value for control and elimination programmes in
areas of low endemicity.
Methods
Study area, subjects, and blood sample collection
This study was carried out in Chabahar, Sistan and
Baluchistan Province in south-eastern Iran. In this area,
most of the patients are adults and may experience
several infections by P. falciparum and P. vivax. In this
investigation, 101 blood samples were obtained from sus-
pected patients attended at the Malaria Health Center
in Chabahar Public Health Department in Sistan and
Baluchistan Province from May 2006 to 2012. Before
blood collection, an informed consent was obtained from
adults or parents or legal guardians of children who were
participant in this study. The diagnosis of malaria was
made by microscopic examination of blood smears stained
with Giemsa. All P. falciparum-positive samples were
verified by molecular diagnosis using the 18ssrRNA gene
as described previously [56]. The control blood samples
(n = 30) were obtained from the residents in Tehran (Iran)
with no known pervious exposure to malaria. From all
subjects, 2 ml venous blood was collected for both Plas-
modium DNA detection and serum collection in EDTA
tubes. The collected blood samples were transported on-
ice to the main laboratory in the Institut Pasteur Iran. The
majority of the patients were male (75.2%) with a mean
age of 29.9 ± 12.6 years (ranged between 4 to 75 years
old). The patients’ travel histories were obtained by a
physician prior to sampling. The demographic informa-
tion of the examined groups is shown in Table 1. This
study was approved by the Ethical Review Committee of
Research in Institut Pasteur Iran.
Cloning and sub-cloning of PfAMA-1
Parasite genomic DNA was prepared from the whole
blood by using the commercially available DNA Purifica-
tion Kit (Promega, Madison, WI, USA). The DNA was
dissolved in 30 μl TE buffer (10 mM Tris–HCl, pH 8.0,
0.1 mM EDTA) and kept at −20°C until use. In this
study, for the expression of recombinant PfAMA-1
(rPfAMA-1), DNA samples with known sequences ofTable 1 Demographic characteristics of the examined subject
Mean
age ± SD
Sex (%) Exposure (%)
Male Female First exposure More than one ex
29.9 ± 12.6 75.2 24.8 48.5% 51.5%PfAMA-1 (GenBank accession no. KC413989) were se-
lected based on previous study [57]. Amplification of
PfAMA-1 fragment corresponding to amino acids 96–542
(nucleotides: 286–1626) was performed using the following
primers:
PfAMA-1-AF:AGCGGAGGATCCAGCATTGAAATAG
TAGAAAGAAG, BamHI site (italic)
PfAMA-1-AR: AGGGCCAAGCTTCATAAGTTGGTT
TATGTTCAG, HindIII site (italic)
The PCR was performed at 95°C for 5 min, 30 cycles
at 94°C for 1 min, 60°C for 1 min, 72°C for 1 min,
followed by 60°C for 2 min and final extension at 72°C
for 30 min. The PCR products were analysed by electro-
phoresis on 1% agarose gel under an ultraviolet light and
purified by QIA quick Gel Extraction Kit (Qiagen,
Germany). The gel-purified PCR products were cloned
into pGEM-T Easy Vector (Promega, USA) and trans-
formed into Escherichia coli DH5α. The transformed
clones were selected on the Luria-Bertani agar medium,
containing 100 μg/ml ampicillin, 1.5 mM isopropyl-β-D-
thiogalactopyranoside (IPTG), and 0.04% X-gal. Positive
clones were confirmed by plasmid isolation, followed by
digestion with EcoRI, and the cloned fragments were then
sequenced. Fragments corresponding to the PfAMA-1 se-
quence were excised with restriction enzymes (BamHI
and HindIII) and ligated to the BamHI-HindIII sites of
vector pQE-30 (Qiagen, Germany), which provides a
poly-histidine (6-His) tag in N-terminus to facilitate fur-
ther purification. The ligation mixtures were transformed
into competent E. coli DH5α cells, and the recombinant
clones were selected on ampicillin plates. The open
reading frame was confirmed by sequencing, and this
construct was used to transform E. coli M15 (pREP4)
expression host (Qiagen, Germany).
Expression and purification of rPfAMA-1
rPfAMA-1 was expressed in E. coli M15. Briefly, overnight
cultures from single colonies of PfAMA-1-specific E. coli
were expanded in TB (Terrific broth; pH 7.2), containing
ampicillin (100 μg/ml) and kanamycin (25 μg/ml) with
shaking (150 rpm) at 37°C until an optical density (OD) of
0.6 to 0.7 at 600 nm was reached. The expression of
PfAMA-1 was induced with 0.5 mM IPTG (Sigma, USA).
The culture was further grown for 4 h, and the E. coli cells
were harvested by centrifugation and kept in −80°C until
use. PfAMA-1 was expressed in inclusion bodies, and the
cell pellet was dissolved in denaturation buffer (8 M Urea,
30 mM imidazole, 20 mM Tris–HCl, and 1 M NaCl,s in this study
Nationality (%) Travel history (%)
posure Iranian Pakistani Afghani Yes No
48.5 44.5 6.9 49.5 50.5
Rouhani et al. Malaria Journal  (2015) 14:58 Page 4 of 14pH 7.9). The cells were lysed on ice by sonication (Ultra-
schallprozessor, Germany) with 10 cycles, each consisting
of 20- second (s) pulses with 20-s intervals. The bacterial
lysate was centrifuged at 14,000 × rpm at 4°C for 30 min.
The supernatant was incubated with Ni2+-nitrilotriacetic
acid agarose resin (Ni-NTA Agarose, Qiagen, Germany)
at 4°C for 2 h, and the resin was packed into a column
and was washed with a 10-column volume of wash buf-
fer (6 M urea, 20 mMTris-HCl, 1 M NaCl, and 60 mM
imidazole, pH 7.9). The bound protein was eluted with
a buffer, containing 4 M urea, 200 mM imidazole,
20 mM Tris–HCl, and 300 mM NaCl, pH 7.9. The frac-
tions containing PfAMA-1 was desalted with Econo-Pac
10DG columns (BioRad, USA) according to the manufac-
ture’s manual and then concentrated with a concentrator
(Eppendorf, Germany). The eluted proteins were analysed
under reducing (with 1% SDS and 2% β-mercaptoethanol
[2ME]) and non-reducing conditions (with SDS and with-
out 2ME) by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE, 12%). The concentration of
the protein was determined using Bradford’s assay by a
spectrophotometer (Eppendorf, Germany). To confirm
the purified recombinant proteins, Western blot assay was
carried out by standard protocols using anti-His antibody
(Penta His Antibody; Qiagen) and with P. falciparum-in-
fected human sera that reacted with rPfAMA-1 under
both reducing and non-reducing conditions. Protein
migration at different sizes on SDS-PAGE in the presence
and absence of 2ME indicates the presence of a disulfide
bound, suggesting that all recombinant proteins had a ter-
tiary shape in their antigens.
Expression and purification of recombinant PfMSP-119
(rPfMSP-119)
rPfMSP-119 was expressed as described previously [11].
Briefly, rPfMSP-119 protein was expressed in E. coli BL21.
Overnight cultures from single colonies of PfMSP-119−
specific E. coli were expanded in TB (pH 7.2) containing
ampicillin (100 μg/ml) at 37°C with shaking (150 rpm)
until an OD of 0.6-0.7 at 600 nm was reached. In addition,
the expression of GST-PfMSP-119 was induced with
0.5 mM IPTG (Sigma, USA). The culture was further
grown for 4 h, and the E. coli cells were harvested by
centrifugation and kept in −70°C until use. The cell pellet
was dissolved in PBS 1× (pH 7.4) and lysed on ice with 10
sonication cycles (Ultraschall-Prozessor, Germany), each
consisting of 20-s pulses at 20-s intervals. The bacterial
lysate was centrifuged at 14,000 × g at 4°C for 30 min. The
supernatant was incubated with glutathione 4B Sepharose
resin (Amersham Biosciences, USA) at 4°C for 1 h, and
the resin was packed into a column. The column was
washed with PBS 1×, pH 7.4 (10-column volume). The
bound protein was eluted with a buffer, containing 50 mM
Tris–HCl and 10 mM reduced glutathione, pH 8. Thefractions containing PfMSP-119 were desalted with Econo-
Pac 10 DG columns (BioRad, USA) according to the
manufacturer’s manual and then concentrated with a
concentrator (Eppendorf, Germany). The eluted proteins
were analysed under reducing (with 1% SDS and 2% 2ME)
and non-reducing conditions (with SDS and without
2ME) by SDS-PAGE (12%), and the concentration of
the protein was determined using Bradford's assay by a
spectrophotometer (Eppendorf, Germany).
Mice immunization
Inbred BALB⁄c female mice (6–8 weeks old) were obtained
from Laboratory Animal Science Department, the Institut
Pasteur Iran. Mice groups (n = 7) were immunized sub-
cutaneously at the base of tail with 30 μg and 35 μg of the
rPfAMA-1and rPfMSP-119, respectively. In priming and
boosting, the antigens were then emulsified in complete
Freund's adjuvant (CFA, Sigma, St. Louis, MO, USA) and
with incomplete Freund's adjuvant (IFA, Sigma) in 1:1
ratio. The mice control groups were immunized with PBS
alone, PBS in Freund's adjuvant and rGST alone. The ani-
mals were boosted on days 14 and 28 and bled on days 0
(pre-immune), 21, and 35 of first immunization.
Indirect immunofluorescence antibody test (IFAT)
IFAT assay was performed to test the ability of the anti-
PfAMA-1 and anti-PfMSP-119 sera of immunized mice,
to recognize the native form of both antigens on mero-
zoite surface and to determine the similarity between
epitopes in recombinant forms and corresponding native
proteins. For this purpose, multispot slides of parasites
were prepared from P. falciparum culture, air-dried and
then fixed in cold acetone for 10 min. Polyclonal mouse
sera diluted (1:100–1:12,800) in PBS were added to the
spots and incubated in a wet chamber for 60 min. After
washing three times with PBS (pH 7.4), each well was
covered with 20 μL of the fluorescein-conjugated anti-
mouse polyvalent IgG (1:40) and then left in a wet
chamber for 40 min. Again, after washing three times
with PBS, coverslips were placed on each slide and
examined under a fluorescence microscope (Nikon E200,
Tokyo, Japan) with an oil immersion objective (100×). The
serum samples obtained from normal mice were used as
negative controls.
Comparative analysis of ELISA assays using single or
combined rPfAMA-1 and rPfMSP-119
In the present study, IgG antibody responses of individuals
during acute infection to rPfAMA-1 and rPfMSP-119 anti-
gens (as single or in combination) were measured by an
ELISA as described previously with some modifications
[11]. In brief, Maxisorp flat-bottomed 96-well microplates
(Grainer, Labortechnic, Germany) were coated duplicate
with 200 ng of either rPfAMA-1 or rPfMSP-119 and in
A B
C D E F
Figure 1 IFAT for recognition of native form of AMA-1 and
MSP-119 on the P. falciparum parasites with polyclonal antibodies
induced in mice. Green fluorescence is visible due to the recognition
of surface AMA-1 and MSP-119 on P. falciparum merozoite by sera of
the mice immunized with (A) rPfAMA-1+ CFA/IFA (n = 7); (B) rPfMSP-
119 + CFA/ICFA (n = 7); (C) GST + CFA/ICFA (n = 7); (D) PBS + CFA/ICFA
(n = 7); (E) PBS (n = 7); (F) normal mouse sera (n = 7). CFA: Complete
Freund's adjuvant; IFA: Incomplete Freund's adjuvant.
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200 ng of each antigen/well) or GST alone (as control)
in 0.06 M carbonate-bicarbonate buffer (pH 9.6) and
then incubated at 4°C overnight. The plates were washed
with PBS-Tween (PBS-T) and blocked with bovine serum
albumin (BSA)-PBS-0.05% Tween. Serum was added in
duplicate at a dilution of 1:200 (in BSA-PBS-0.05% Tween,
100 μl/well). After washing with PBS-T, the plates were
incubated with horseradish peroxidase-conjugated goat
anti-human IgG (Sigma, USA) at 1:35,000 concentra-
tion. Finally, the enzyme reaction was developed with
o-phenylediamine dihydrochloride-H2O2 (OPD, Sigma,
USA) and stopped with 2 N H2SO4. The OD was mea-
sured using an ELISA microplate reader (Biotech, USA)
at 490 nm. All samples were re-tested if there was a
discrepancy of greater than 20% between the duplicates.
Standardization of the plates was achieved using positive-
control serum pools on each plate. Background (deter-
mined from the wells with either no serum or GST) was
subtracted from the mean of each sample, and a cut-off
value was determined as the mean plus three standard
deviations from the 30 negative control serum samples
which were included in each assay.
Statistical analysis
A database was generated with SPSS 20.0 for windows
(SPSS Inc., USA). As the antibody levels were not normally
distributed, non-parametric tests were used. Differences in
the proportions of IgG-positive subjects were assessed
using the McNemar's test or Chi square comparison of pro-
portions as appropriate. Furthermore, differences between
the mean absorbance of antigens alone or in combination
were analysed by using Wilcoxon Signed Ranks test or
Friedman test as appropriate. The Spearman’s correlation
test was also used to assess the association between anti-
body levels with age as well as exposure. P values < 0.05
were considered statistically significant. The sensitivity of
each test was measured by dividing the number of positive
IgG sera to total numbers of sera obtained from P. falcip-
arum-infected individuals.
Results
Detection of P. falciparum parasites by nested PCR
Based on both microscopy and nested-PCR results, all 101
patients were shown to be infected with P. falciparum, as
a mono-infection, and none of the healthy control individ-
uals had either P. falciparum or P. vivax infection.
Recognition of native PfAMA-1 and PfMSP-119 on the
surface of P. falciparum merozoite by mice polyclonal
antibodies to rPAMA-1 and rPfMSP-119
Anti-rPfAMA-1 and -rPfMSP-119 produced in mice rec-
ognized the native protein present on the surface of P.
falciparum merozoite at late schizont (or merozoite)stage with high intensity, as indicated by the grape-like
fluorescence pattern (Figure 1A and B). Moreover, none
of the control mice sera recognized the native protein on
P. falciparum parasite (Figure 1C, D, E, and F), confirming
that there are common epitopes in recombinant forms
that correspond to native proteins. The reduced and non-
reduced SDS-PAGE as well as Western blot analysis also
confirmed that rPfAMA-1 (~55 kDa) and rPfMSP-119
(37.5 kDa) proteins had proper conformation and folding.
Antibody responses to rPfAMA-1 antigen
PfAMA-1 was expressed in E. coli M15-pQE30, and the
purified protein was analysed by SDS-PAGE with a mo-
lecular mass of ~55 kDa. The purity of the recombinant
proteins was evaluated by Western blot assay. The result
showed that expressed proteins migrated at different
sizes in the presence and absence of 2ME contained a
disulfide bound. Total IgG antibody responses to PfAMA-1
was determined in 101 individuals (aged 4 to 75 years;
median = 27 years; Table 2) and only 87.1% (88/101) had
positive IgG antibody responses to rPfAMA-1 antigen
(Figure 2). None of the sera from healthy individuals
(control group) contained IgG antibody to rPfAMA-1,
which confirms the specificity of the present results.
IgG subclass response to rPfAMA-1 antigen
Serum samples positive for total anti-rPfAMA-1 IgG were
evaluated for IgG subclass responses to rPfAMA-1 anti-
gen. In individuals who were infected with P. falciparum,
Table 2 Comparative analysis of the level of IgG and subclass antibodies to rPfAMA-1 and rPfMSP-119 antigens among
individuals with patent P. falciparum infection from south-eastern Iran
Antigen Mean OD490 ± SD
IgG IgG1 IgG2 IgG3 IgG4
PfAMA-1 1.096 ± 0.393 1.307 ± 1.001 0.232 ± 0.027 0.938 ± 0.436 0.502 ± 0.144
Frequency of responders (%) 88 (87.1) 88 (87.1) 9 (8.9) 36 (35.6) 4 (4)
Cut-off 0.284 0.273 0.2 0.37 0.25
PfMSP-119 1.467 ± 0.619 1.654 ± 0.802 0.404 ± 0.191 0.936 ± 0.430 0.467 ± 0.088
Frequency of responders (%) 85 (84.2) 84(83.2) 10 (9.9) 44 (43.6) 4 (4)
Cut-off 0.323 0.319 0.215 0.357 0.2
P value (Spearman’s correlation test) <0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001
The mean OD490 nm value was considered as a measure of the anti-PfAMA-1 or -PfMSP-119 -specific antibody responses of each serum sample by ELISA assay.
The cut-off values were calculated by mean ODs of normal human sera (n = 30) out of malaria- endemic areas plus 3 standard deviation (SD). There was a
significant correlation among the mean ODs of IgG, IgG1, IgG2, IgG3, and IgG4 to PfAMA-1 and PfMSP-119 antigens (IgG, r = 0.603, P <0.0001, IgG1, r = 0.593,
P < 0.0001; IgG2, r = 0.433, P < 0.0001; IgG3, r = 0.457, P < 0.0001; and IgG4, r = 0.464, P < 0.0001; Spearman’s correlation test).
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and Table 2) was the dominant subclass. The second fre-
quent subclass was IgG3 (35.6%, OD490 = 0.938, Figure 2
and Table 2). In case of IgG2 and IgG4, the frequency
distribution of individuals that recognized the antigen was
8.9% and 4% (mean OD490 = 0.232 and 0.502, respectively;
Figure 2 and Table 2). Furthermore, heterogeneity in IgG1
and IgG3 isotype responses was observed (Table 3). The
results indicated that IgG1 and IgG3 were predominant
over IgG2 and IgG4 antibodies. In addition, there were
significant differences among the levels of IgG, IgG1,
IgG2, and IgG4 antibodies (Friedman test, P < 0.05).
Antibody responses to rPfMSP-119 antigen
PfMSP-119 was expressed in E. coli BL21-pGEX-KG,
and the purified protein was analysed by SDS-PAGE
with a molecular mass of ~37.5 kDa. The purity of theFigure 2 Prevalence of IgG and its subclass responses to rPfAMA-1 an
patent infection (n = 101) from malaria-endemic area of Iran. No signif
and IgG4 responses to PfAMA-1 and PfMSP-119 antigens (P > 0.05; McNemar's
0.273, IgG2: 0.2, IgG3: 0.37, and IgG4: 0.25 for PfAMA-1 antigen; IgG: 0.323, IgGrecombinant protein was evaluated by Western blot
assay. The result showed that the expressed PfMSP-119
migrated as a single homogeneous band on SDS-PAGE
under non-reducing conditions, indicating that it is largely
composed of a single conformer. Total IgG antibody re-
sponses to rPfMSP-119 was determined in 101 individuals
(aged 4 to 75 years; median = 27 years; Table 1) and only
84.2% (85/101) had positive IgG antibody responses to
rPfMSP-119 antigen (Figure 2). None of the sera from
healthy individuals (control group) contained IgG anti-
bodies to PfMSP-119, which confirms the specificity of the
present results.
IgG subclass response to rPfMSP-119 antigen
Serum samples positive for total anti-PfMSP-119 IgG were
evaluated for IgG subclass responses to rPfMSP-119 anti-
gen. In individuals who were infected with P. falciparum,d rPfMSP-119 antigens among individuals with P. falciparum
icant difference was observed in the proportions of IgG, IgG1, IgG2, IgG3,
test). The cut-off values of the controls were as follow: IgG: 0.284, IgG1:
1: 0.319, IgG2: 0.215, IgG3: 0.357, and IgG4: 0.2 for PfMSP-119 antigen.
Table 3 The heterogeneity in IgG1 and IgG3 responses to rPfAMA-1 and rPfMSP-119 antigens in individuals with
patent P. falciparum infection, living in Chabahar district of Iran
Antigen IgG1+/IgG3+ no. (%) IgG1+/IgG3− no. (%) IgG1−/IgG3+ no. (%) IgG1−/IgG3− no. (%) χ2 test P value
PfAMA-1 36 (35.6) 52 (51.5) 0 13 (12.9) = 0.357
PfMSP-119 43 (42.6) 41(40.6) 1 (0.99) 16 (15.8)
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and Table 2) was the dominant subclass. The second fre-
quent subclass was IgG3 (43.6%, OD490 = 0.936, Figure 2
and Table 2). In case of IgG2 and IgG4, the frequency
distribution of individuals that recognized the antigen was
9.9% and 4% (mean OD490 = 0.404 and 0.467, respectively;
Figure 2 and Table 2). Furthermore, heterogeneity in IgG1
and IgG3 isotype responses of individuals was observed
(Table 3). The results indicated that IgG1 and IgG3 were
predominant over IgG2 and IgG4 antibodies. In addition,
there were significant differences among the levels of IgG,
IgG1, IgG2, IgG3, and IgG4 antibodies (Friedman test,
P < 0.05).
Exposure- and age-dependent IgG, IgG1, and IgG3
responses
The levels of IgG, IgG1, and IgG3 antibodies to
rPfAMA-1 were not correlated with exposure (r = 0.061,
P = 0.544 for IgG; r = 0.042, P = 0.673 for IgG1, and
r = 0.014, P = 0.893 for IgG3; Spearman’s correlation test)
or age (r = 0.082, P = 0.416 for IgG; r = 0.060, P = 0.550
for IgG1, and r = 0.172, P = 0.085 for IgG3; Spearman’s
correlation test). Likewise, the levels of IgG, IgG1, and IgG3
antibodies to the rPfMSP-119 were not correlated with
exposure (r = 0.104, P = 0.302 for IgG; r = 0.013, P = 0.895
for IgG1, and r = −0.022, P = 0.826 for IgG3; Spearman’s
correlation test) or age (r = 0.128, P = 0.2 for IgG; r = 0.078,
P = 0.435 for IgG1, and r = 0.118, P = 0.242 for IgG3;
Spearman’s correlation test).
Regarding the analysis of the correlation between the
frequency of IgG antibodies and age, the sera of the 101
individuals were separated into three groups: (i) 1–15
years old (n = 8), 16–30 years old (n = 53), and ≥ 31 years
old (n = 40). No significant difference was found in the
prevalence of positive sera for PfAMA-1 and PfMSP-
119-specific IgG, IgG1 and IgG3 antibodies in different
age groups (Chi-square, P > 0.05, Figure 3A and B), indi-
cating that antibody responses against PfAMA-1 and
PfMSP-119 were not correlated with age. It was then
determined whether there was a correlation between the
frequency of IgG antibodies and episodes of P. falcip-
arum infection. For this purpose, the sera of the 101
individuals were separated into two groups: (i) primary
infected, individuals with no previous malaria episodes
(n = 49) and (ii) individuals with one or more previous
malaria episodes (n = 52). The frequency of responders
to both antigens did not change significantly when theydivided in primary and multiple-infected (Chi-Square
test, P > 0.05) confirming that antibody response against
PfAMA-1 and PfMSP-119 was established after a single
exposure to malaria (Figure 4A and B). This result shows
that specific IgG responses to both antigens are devel-
oped after even one malaria episode.
Comparative analysis of the naturally acquired antibody
responses to rPfAMA-1 and rPfMSP-119 antigens
The frequency of individuals with IgG antibodies to
combined antigens (100 ng of each antigen/well) was only
86.2% during patent infection with P. falciparum. No
response to either antigen was observed in 13.8% of the
individuals (Figures 5 and 6; Table 4). The difference in
the prevalence of anti-PfAMA-1 and -PfMSP-119 IgG
responses in the tested samples was not statistically signifi-
cant (with mean OD490 = 1.096 ± 0.393 and 1.467 ± 0.619;
cut-offs 0.284 and 0.323, respectively; P = 0.25, McNemar's
test; Table 4). None of the sera from control groups con-
tained anti-PfAMA-1 and/or -PfMSP-119 IgG antibodies.
The present data confirmed that the two antigens were
immunogenic during natural infections. However, when
rPfAMA-1 and rPfMSP-119 were combined at equal ratios
of 200 ng (100 ng each antigen/well) and 400 (200 ng each
antigen/well), sero-positivity of 86.2% and 87.1% were
obtained, respectively (Figure 6, Table 4). Interestingly, 3%
(3/101) of the tested samples had positive IgG antibody
responses to rPfAMA-1 but not to rPfMSP-119 antigens, in-
dicating the higher sensitivity of rPfAMA-1 than rPfMSP-
119 (Figures 5 and 6, Table 4). There was also statistically
difference among the mean absorbance of antibodies to
both antigens when used in ELISA either alone or in
combination (P < 0.05, Friedman test). However, when
the mean absorbance was compared in paired groups,
no significant difference was observed in the mean ab-
sorbance of antibodies to combination of rPfAMA-1 and
rPfMSP-119 at concentration of either 200 ng or 400 ng
(P > 0.05, Wilcoxon Signed Ranks test).
Discussion
In elimination programmes, reduction in disease and death
due to P. falciparum is the primary objective. Although
the prospects of achieving global malaria eradication have
been diminished by the limited available intervention
tools, vaccines could be considered effectively in these
programmes; for instance, they have also vital role in
global eradication of smallpox and the elimination of
AB
Figure 3 Association between age and IgG, IgG1, and IgG3 antibody responses to rPfAMA-1 (A) and rPfMSP-119 (B) antigens. The
prevalence of positive responders for IgG, IgG1, and IgG3 antibodies for each age group is shown in the Figure. In the different age groups, no
significant difference was observed in the prevalence of responders to PfAMA-1 and PfMSP-119 antigens for IgG, IgG1, and IgG3 (P > 0.05, X
2 test).
Age groups are: 1–15 years (n = 8), 16–30 years (n =53), and≥ 31 years (n = 40).
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opment, sero-epidemiology studies on various populations
with a different genetic background and endemicity in
malaria settings would help to understand the host
immune responses to malaria parasites as well as the
endemicity of the disease. Besides, in malaria elimin-
ation programmes, monitoring changes in transmission
intensity and identification of residual foci of malaria
by using sensitive and reliable tools is very important for
measuring the success of the programme. Therefore, the
goal of this study was to compare and analyse the natur-
ally acquired antibody responses to two recombinant
proteins representing two asexual erythrocytic stage of
P. falciparum (PfAMA-1 and PfMSP-119) by human IgG
antibodies among naturally exposed individuals living in
the malaria hypoendemic setting, Iran. These two pro-
teins not only are the asexual erythrocytic stage vaccine
candidates but also are serological markers particularly
useful for detection of relative antibody responses in areas
of low endemicity [53,58].In the present investigation, both antigens were pro-
duced in E. coli, and the results showed that both
expressed proteins were folded correctly and suitable for
ELISA. The value of using recombinant protein in vac-
cine development against malaria has been also shown
in earlier studies. These surveys demonstrated that the
cysteine-rich sequence of PfMSP-119 with two epidermal
growth factor (EGF)-like motifs [59] could be expressed
in E. coli in a correctly folded manner [46], and that it
plays an important role in the induction of protective
immunity [60]. In addition, the protection elicited by
AMA-1 is directed at epitopes dependent on the disul-
fide bonding [61] located in the AMA-1 ectodomain;
hence, the correct conformation is critical for AMA-1
based vaccine development.
In elimination and eradication strategies, understanding
the immunity to malaria parasites is crucial for successful
and reliable interventions. The Iranian government aims
to eliminate this poverty-related disease from malaria-
endemic settings, mostly close to Pakistan and Afghanistan
AB
Figure 4 Association between episodes of P. falciparum infection and IgG, IgG1, and IgG3 antibody responses to PfAMA-1 (A) and
PfMSP-119 (B) antigens. In the individuals with different malaria episodes (P > 0.05, X
2 test), no significant difference was observed in the prevalence
of responders to PfAMA-1 and PfMSP-119 antigens for IgG, IgG1, and IgG3. The groups are: (i) no previous malaria episodes (n = 49) and (ii) individuals
with one or more previous malaria episodes (n = 52).
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(<20%) are prevalent. In the present work, the interaction
between the host immune system and parasites showed
that 87.1% and 84.2% of the studied individuals had positive
anti-PfAMA-1 and -PfMSP-119 IgG antibody responses,
respectively, suggesting that both of these expressed anti-
gens are well-recognized asexual-stage parasite antigens.
Although the present finding documents that the frequen-
cies of antibodies to both recombinant antigens are almost
similar in the areas of unstable transmission, the role of
these antibodies in protection to malaria needs further
study. However, the absence of such response in about13% of the individuals could be perhaps explained by
unknown human genetic factors [62] and/or the first or
short exposure to these antigens, which may be insuffi-
cient to induce considerable immune responses. This slow
development of naturally acquired malaria immunity has
been shown by others in low to moderate malaria trans-
mission settings [63,64].
Analysis of IgG isotype response to the PfAMA-1 and
PfMSP-119 antigens is important for evaluating protective
activity as IgG subclasses differ in their immune effector
functions and having such knowledge is important for
understanding the immunity to vaccine development. The
Figure 5 Pattern of total IgG responses to single rPfAMA-1, rPfMSP-119, and combined antigens in individuals infected with P. falciparum
(n = 101). Ages are given in years. Cut-off values were 0.284, 0.323, 0.351, and 0.36 for PfAMA-1, PfMSP-119, combined antigens with 100 ng
of each and 200 ng of each, respectively. The OD mean values have been divided into the following groups: OD > 1.5: High-positive antibody
responses (black). 1 < OD < 1.5: Medium-positive responses (dark gray), OD < 1: Low-positive responses (pale gray), and OD < Cut-off:
Negative (white).
Rouhani et al. Malaria Journal  (2015) 14:58 Page 10 of 14result of the present study confirmed previous studies
[42,54,65,66] that showed IgG1 and IgG3 isotypes were
the predominant subclasses in response to both antigens.
These subclass responses might perhaps relate to antigen
properties, number of exposure, host age, and genetic de-
terminants. The high prevalence of anti-PfMSP-119 IgG1
responses among studied individuals was in contrast to
what was reported from Senegalese adults (in Dielmo and
Ndiop) that a greater proportion of individuals were
anti-MSP-1 IgG3 positive [67]. This finding was inline with earlier report of very little or no IgG3 to
PfAMA-1 [66].
In addition, the present result was in contrast to the pre-
vious report that stated the frequency of PfMSP-119-specific
IgG1 was higher among subjects (living in different areas of
Brazil) with a long-term exposure to malaria, as compared
to the subjects sporadically-exposed [68]. In this study,
although anti-PfAMA-1 and -PfMSP-119 IgG1 was pre-
dominant, there was also a mixed IgG1/IgG3 response as
reported by others [69]. This heterogeneity in IgG1 and
Figure 6 Prevalence of tested samples with positive IgG antibody
responses to either rPfAMA-1 and rPfMSP-119 antigens alone or in
combination (200 and 400 ng of antigens in equal ratio).
Rouhani et al. Malaria Journal  (2015) 14:58 Page 11 of 14IgG3 recognition could be related to either different epi-
topes in PfAMA-1 antigen recognized by these two IgG
subclasses or short half-life of IgG3 antibody in the serum
sample. Moreover, it is well established that IgG1 and IgG3
subclasses mediate opsonization and complement fixation
of pathogens, and they are involved in antibody-mediated
protective immunity against Plasmodium blood stages
[70,71]. Therefore, the finding that IgG subclasses to both
antigens are mainly of the IgG1/IgG3 type with high fre-
quencies indicate that this high prevalence might be associ-
ated with protective effect on cell-mediated mechanisms
from falciparum malaria as shown by others [15,42,65-75].
As the interaction between the host immune system and
parasites differs based on the degree of the malaria endem-
icity, it has been suggested that in malaria high-endemic
areas, the acquisition of natural immunity to P. falciparum
requires several years of uninterrupted exposure [68,76].
However, in hypoendemic or mesoendemic areas, there is
no association between age and exposure to malaria [7-9].
In the present study, in the unstable and low malaria trans-
mission, the frequency of responders to PfAMA-1 and
PfMSP-119 was not correlated with either age or number
of exposure to malaria, which confirms the previous
reports [7-9] and indicates that PfAMA-1 and PfMSP-119
are highly immunogenic during natural human infections.
The present result was also in agreement with the resultTable 4 Prevalence of IgG responses to rPfAMA-1, and rPfMSP





Combined antigens (200 ng/well) 14 (13.8%)
Combine antigens (400 ng/well) 13 (12.9%)of previous studies in low-endemic areas of Senegal [32]
and West Africa [41,77], where no such correlation was
observed. Nevertheless, a statistically significant age-
related change in antibody levels to PfAMA-1 [78] and
PfMSP-119 [79] was observed in the previous studies.
In the advanced phases of malaria elimination pro-
grammes, the technique for assessment of malaria trans-
mission intensity and evaluation of interventions during
this effort are highly required. Recently, there has been a
recall for elimination of malaria with the scaling-up in-
terventions; therefore, malaria burden and transmission
declined across a number of countries [80-82]. In such
situations, serological techniques using reliable markers
could be applied for detecting and targeting clusters of
infection, to reduce the local parasite reservoir and inter-
rupt transmission [83]. In this study, the applicability of
using two serological markers to detect sero-positive cases
in such an unstable, hypoendemic, and low transmission
settings, where the sensitivity of parasite prevalence sur-
veys is limited, was tested. Each antigen was highly spe-
cific and reactive to the tested sera, and the sensitivity of a
single antigen for detection was similar with that of the
two combined antigens. Nevertheless, since 3% of samples
were positive for PfAMA-1 but negative for PfMSP-119,
the present study is in favour of using multiple antigens
for antibody-based detection in this area and other similar
settings during elimination programmes.
Conclusion
In summary, the present results suggest that the two tested
recombinant antigens are immunogenic molecules and use-
ful tools to perform immuno-epidemiological studies in
low transmission areas of Iran. These data also provide, for
the first time, information on the characteristics of naturally
acquired immunity in populations exposed to malaria
transmission in Iran. Indeed, it could be beneficial for
development and testing of a PfAMA-1 and PfMSP-119-
based vaccine in Iran, where malaria is endemic. This study
specially demonstrates high level frequencies of antibodies
to rPfAMA-1 and rPfMSP-119 among individuals infected
with P. falciparum in areas of unstable and low transmis-
sion, indicating that these two expressed antigens could be
used in combination as serology markers during elimin-
ation campaigns in this region.-119 alone and in combination antigens in 101 samples
Positive sera
No. (%)




88 (87.1%) 1.096 ± 0.393 0.284
85 (84.2%) 1.467 ± 0.619 0.323
87 (86.1%) 1.133 ± 0.379 0.351
88 (87.1%) 1.390 ± 0.437 0.351
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